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The highly diverse Numb-associated kinase (NAK)
family has been linked to broad cellular functions
including receptor-mediated endocytosis, Notch
pathway modulation, osteoblast differentiation, and
dendrite morphogenesis. Consequently, NAK ki-
nases play a key role in a diverse range of diseases
from Parkinson’s and prostate cancer to HIV. Due
to the plasticity of this kinase family, NAK kinases
are often inhibited by approved or investigational
drugs and have been associated with side effects,
but they are also potential drug targets. The pres-
ence of cysteine residues in some NAK family mem-
bers provides the possibility for selective targeting
via covalent inhibition. Here we report the first high-
resolution structures of kinases AAK1 and BIKE in
complex with two drug candidates. The presented
data allow a comprehensive structural characteriza-
tion of the NAK kinase family and provide the basis
for rational design of selective NAK inhibitors.
INTRODUCTION
The Numb-associated family of protein kinases (NAKs) constitute
a diverse family in terms of Ser/Thr kinases in both their function
and structure, sharing little conservation outside of the kinase
domain (Smythe and Ayscough, 2003) and as low as 30%
sequence identity across their kinase domains. They are named
for similarity to theDrosophilaproteinNAK,which plays a role dur-
ing asymmetric cell division through its association with Numb.
Humans have four known homologs: AAK1 (adaptor-associated
kinase 1), BIKE/BMP2K (BMP-2-inducible kinase), GAK (cyclin
G-associated kinase), and MPSK1 (myristoylated and palmitoy-
lated serine/threonine kinase 1, also known as STK16).
The NAKs are associated with a broad range of cellular func-
tions. AAK1 has a critical role in receptor-mediated endocytosis,
including direct binding to clathrin and specific phosphorylation
of the medium subunit of AP2 (adaptor protein 2), which is known
to stimulate binding to cargo proteins (Conner and Schmid, 2002;
Henderson and Conner, 2007; Neveu et al., 2012). AAK1 alsomodulates the Notch cell-to-cell signaling pathway by promoting
Notch activation through interaction with a membrane-tethered
form of Notch (Gupta-Rossi et al., 2011). Conversely, the protein
Numb is thought to antagonize Notch signaling by increasing
Notch degradation through polyubiquitination. Phosphorylation
of Numb by AAK1 is a priming step necessary to allow its phos-
phorylation by other kinases (Sorensen and Conner, 2008), and
thereby the role of AAK1 in the Notch pathway has been sug-
gested to be two-fold: priming and redistribution of Numb as
well as Notch activation (Gupta-Rossi et al., 2011). AAK1 is also
a substrate for NDR1/2 phosphorylation and has been shown
to control dendrite morphogenesis in developing mammalian
neurons (Ultanir et al., 2012). BIKE is structurally closely related
to AAK1 and plays a role in osteoblast differentiation, and has
also recently been identified as clathrin-coated vesicle-associ-
ated protein (Borner et al., 2012), and similarly to AAK1 it is
Numb associated (Krieger et al., 2013). GAK is a known associ-
ation partner of cyclin G and CDK5 and among its known func-
tions some are shared with AAK1. It is essential for clathrin traf-
ficking and mediates binding to the plasma membrane and
trans-Golgi network, as well as being required for maintenance
of centrosome maturation and progression through mitosis
(Chaikuad et al., 2014). MPSK1 is the most distantly related of
the family members and its physiological functions remain
poorly understood, although it is known to be a Golgi-associ-
ated kinase with a role in the regulation of secretion in the
constitutive secretory pathway at the trans-Golgi network (In
et al., 2014). In addition, MPSK1 has also been linked to mam-
mary development in mice (Stairs et al., 2005).
Due to their wide-ranging functions, NAKs have been dis-
cussed as potential drug targets; for example, GAK has been
implicated in Parkinson’s, prostate cancer, and osteosarcoma
(Beilina et al., 2014; Perrett et al., 2015; Sakurai et al., 2014;
Susa et al., 2010; Wang et al., 2012) while BIKE has been
associated with myopia (Liu et al., 2009) and AAK1 has
recently been linked to a familial form of motor neuron disease
known as amyotrophic lateral sclerosis (Shi et al., 2014). An
interesting possible new therapeutic role for NAKs is their po-
tential as anti-viral targets: inhibitors of AAK1 and GAK disrupt
hepatitis C virus assembly (Neveu et al., 2012), and targeting
BIKE has been suggested as a potential strategy for the treat-
ment of HIV (Zhou et al., 2008). However, off-target effects
have also been reported for NAK family members; for instance,
potent inhibition of GAK by the cancer drug gefitinib has beenStructure 24, 401–411, March 1, 2016 ª2016 The Authors 401
Figure 1. Sequence Conservation and Domain Organization of NAK Family
(A) NAK family phylogenetic tree. C.e., Caenorhabditis elegans; D.m., Drosophila melanogaster; H.s., Homo sapiens; M.m.,Mus musculus; S.c., Saccharomyces
cerevisiae.
(B) Domain organization of human NAKs.
(C) Sequence alignment of human NAK catalytic domains colored by residue conservation. Secondary structure as well as structural elements important for NAK
function and inhibitor interactions are highlighted (green arrow, b sheet; red cylinder, a helix; blue cylinders, NAK-specific helices; yellow triangle indicates the
active-site cysteine important for covalent inhibitor binding; red hexagon indicates regulatory spine residues; residues boxed in orange indicate the position of
mutated residues in BIKE that have been introduced to aid crystallization).linked to respiratory side effects in lung cancer patients (Tab-
ara et al., 2011).
Previously we have solved the crystal structures of both
MPSK1 and GAK, revealing atypical kinase activation segment
architecture (Chaikuad et al., 2014; Eswaran et al., 2008). Here,
we determined high-resolution crystal structures of the two
remaining family members, AAK1 and BIKE, now enabling fam-
ily-wide structural analysis of these interesting signaling mole-
cules. Our analysis revealed target-specific structural features
that may help to design specific chemical probes, which would
help to delineate the complex functional roles of this unusual
kinase family as well as provide models for our understanding
of NAK off-target activity. To facilitate this, we screened a library
of clinically used compounds against the kinase domain of
each of the four NAK family members. Strikingly, our data
show that the NAKs are able to accommodate a wide variety
of ligands, suggesting excellent druggability of NAK kinases.
The presented data provide a basis for rational design of selec-
tive NAK inhibitors as well as highlighting interactions of late-
stage drug candidates.402 Structure 24, 401–411, March 1, 2016 ª2016 The AuthorsRESULTS AND DISCUSSION
Phylogenetic analysis (Figure 1A) revealed that within the NAK
family, hGAK and hMPSK1 cluster on separate branches of the
tree along with their non-mammalian homologs, whereas the
AAK1 and BIKE branches cross over due to the higher degree
of sequence homology. AAK1 and BIKE are more closely related
to the founding member of the family, NAK. Human MPSK1 has
around 33% identity with NAK across the kinase domain. The
yeast homolog ARK1 has 38% similarity to NAK in the kinase
domain; it and several other yeast homologs, such as PRK1,
cluster on a separate branch of the tree.We found that the place-
ment of the kinase domain is evolutionarily conserved within the
family, being situated close to the N terminus of the protein.
Outside of the kinase domain, however, there is wide variation.
For instance, the four human NAK family members bear only
little resemblance to one another outside of the kinase domain,
greatly varying in size and domain organization (Figure 1B).
AAK1 and BIKE are the most closely related, with an overall
sequence identity of 50%, rising to 74% across their kinase
Table 1. Crystallographic Data Collection and Refinement
Statistics
Complex AAK1 K252a
BIKE
AZD7762
BIKE
Baricitinib
PDB ID 4wsq 4w9w 4w9x
Data Collection
Space group P212121 I222 I222
Cell constants:
a, b, c (A˚);
a, b, g ()
68.6, 71.3,
183.6; 90,
90, 90
42.2, 112.7,
163.1; 90,
90, 90
42.3, 111.4,
163.8; 90,
90, 90
Resolution (A˚)a 56.32–1.95
(2.00–1.95)
33.34–1.72
(1.75–1.72)
33.00–2.14
(2.20–2.14)
Unique
observationsa
66,564
(4,379)
41,784
(2,190)
21,713
(1,780)
Completeness (%)a 99.8 (100.0) 99.7 (99.9) 99.0 (99.3)
Redundancya 4.7 (4.8) 6.2 (6.0) 2.6 (5.0)
Rmerge
a 0.10 (1.09) 0.06 (0.87) 0.10 (0.86)
MnI/s(I)a 8.3 (2.1) 15.1 (2.0) 9.6 (2.1)
CC(1/2)
a,b 99.7 (79.4) 99.9 (81.0) 99.3 (65.9)
Refinement
Resolution (A˚) 1.95 1.72 2.14
MR model 2buj 4wsq 4wsq
Copies in ASU 2 1 1
Rwork, Rfree 0.182, 0.208 0.168, 0.195 0.195, 0.233
No. of atoms 5,271 2,662 2,442
Average B
factor (A˚2)
43.0 37.0 38.0
Rmsd (bonds) (A˚) 0.013 0.017 0.018
Rmsd (angles) () 1.273 1.478 1.787
Crystallization 20% PEG
3350, 5 mM
zinc acetate,
293 K
4 M sodium
formate,
293 K
4 M sodium
chloride, 0.1 M
bis-Tris (pH 5.5),
293 K
ASU, asymmetric unit; rmsd, root-mean-square deviation.
aValues in parentheses indicate data for the highest-resolution shell.
bMn(I) half-set correlation as reported by Aimless.domains. GAK and MPSK1 are much more distantly related,
having only 39% and 30% sequence identity, respectively, to
AAK1 over their kinase domains and marginally higher sequence
identity with BIKE (40% and 30%) (Figure 1C).
Family-wide Comparison Reveals Unique NAK Family
Structural Features
To better understand the structural relationship across the
NAK family, we solved the crystal structures of human AAK1
and BIKE. The structure of AAK1 was solved in complex with
a small-molecule inhibitor to 1.95 A˚ resolution in space group
P212121 with two AAK1 kinase domains per asymmetric unit
(chains A and B) (Table 1). Both chains were similar in conforma-
tion with differences only at the N and C termini (Figure 2A). In
chain A, the end of the C terminus forms part of an a helix that
extends outward from the kinase domain into a solvent channel
in the crystal (Figure S1). The predicted secondary structure for
this area agrees with our model, suggesting that the observed
helix is not induced by crystal contacts. The best-diffractingcrystals of AAK1 grew from a set of conditions containing a
high concentration of zinc. There were several strong electron
density peaks with coordination geometry and bonding dis-
tances indicative of metal ions likely representing bound zinc
ions. One such electron density peak was observed at the
catalytic magnesium binding site adjacent to the ATP binding
pocket, indicating that zinc has replaced magnesium in this
site (Figure S1). Calculation of an anomalous difference Fourier
map also showed that the ions are most likely to be zinc and
not magnesium, although probably not at full occupancy. Given
the high zinc concentrations in the experiment, it seems unlikely
that under physiological conditions zinc would occupy these
sites.
More than 50 BIKE kinase domain-containing constructs
were prepared, but fewer than ten were found to express a
reasonable yield of soluble protein, and of these none yielded
crystals. In an attempt to increase the crystallizability of one
of the well-expressing constructs (BIKE residues S38–E345),
six different surface-entropy-reduction (SER) mutants were
prepared. In the SER constructs, up to three lysine residues
on the surface of the protein were truncated to a lower-entropy
alanine residue, to improve the likelihood of forming good crys-
tal contacts (Longenecker et al., 2001). A BIKE38–345, K320A,
K321A construct gave crystals that diffracted well. Crystal
structures of BIKE comprised one molecule per asymmetric
unit, in space group P212121, and were refined at 1.72 and
2.14 A˚ resolution for two different inhibitor co-crystals (Table 1
and Figure S1). The SER mutations reside near the C terminus
and were designed to have little effect on the overall function
of the protein, since they lie at a distant position from the ATP
and substrate binding sites. Surprisingly, the mutated residues
do not participate directly in any crystal-packing contacts, but
it is plausible that the mutation K320A prevents electrostatic
repulsion or a direct steric clash with the side chain of R13
from a symmetry neighbor, making crystallization more favor-
able (Figure S1).
The determination of crystal structures for AAK1 and BIKE
presented here resulted in a complete structural coverage of
the human NAK family. In addition, of the available GAK struc-
tures, two distinct conformations have been reported (Chaikuad
et al., 2014); an inactive dimeric form where the activation
segment of one monomer is exchanged with the second unit of
the dimer; and an active monomeric formwith fully folded activa-
tion segment, which closely resembles the activation segment
architecture of MPSK1 (Eswaran et al., 2008). The structures of
AAK1 and BIKE bear closest resemblance to the monomeric
form of GAK (PDB: 4c57) comprising a canonical bilobal catalytic
domain structure (Figure 2A). While catalytic domain structural
elements are usually tightly conserved in protein kinases, the
NAK family has previously been shown to diverge from usual
kinase structure by the addition of a large a-helical insert, posi-
tioned C-terminal to the activation segment, named the activa-
tion segment C-terminal helix (ASCH). The activation segment
of protein kinases has been termed the ‘‘most important regu-
latory element,’’ whose conformation has a direct impact on
both substrate interactions and catalytic efficiency (Kornev and
Taylor, 2010). Our structures of AAK1 and BIKE now confirm
the existence of the atypical activation segment architecture in
all NAK family members (Figure 2A).Structure 24, 401–411, March 1, 2016 ª2016 The Authors 403
Figure 2. Crystal Structures of Human NAK
Family Kinase Domains
(A) Overlay of crystal structures of AAK1 (gray,
PDB: 4wsq), BIKE (orange, PDB: 4w9w), GAK
(green, PDB: 4o57), and MPSK1 (pink, PDB: 2buj)
showing location of the activation segment C-ter-
minal helix (ASCH). See also Figure S1.
(B) Comparison of ASCH in MPSK1 versus AAK1.
(C) Alignment of R spine in BIKE.
(D) Sedimentation velocity of phosphorylated
AAK1 showing that it is monomeric in solution.
(E) Sequence and structure alignment of NAKs,
with conserved residues shown in violet, non-
conserved residues in white, non-aligned residues
in gray.The ASCH in MPSK1 is positioned by an anti-parallel b-sheet
segment that connects the activation segment and the aE/aF
loop (Figure 2B) (Eswaran et al., 2008). In monomeric GAK, a
similar array of stabilizing interactions exists across the loop. In
AAK1 hydrogen bonds link residues Q203, N-terminal of the
ASCH, to I239 in the aE/aF loop, and similarly in BIKE, corre-
sponding interactions exist between L207 and I243. In general,
however, the network of interactions that is observed in
MPSK1 and GAK is disrupted in the crystal structures of AAK1
and BIKE (Figure 2B). Furthermore, in both AAK1 and BIKE the404 Structure 24, 401–411, March 1, 2016 ª2016 The AuthorsASCH is shorter comprising three turns,
compared with four in MPSK1 and GAK.
Residues 204–208 in AAK1 (and equiva-
lent residues in BIKE) are stabilized by a
series of intramolecular interactions to
form a short turn that is separated from
the rest of the ASCH by a single glycine
residue, which offers greater conforma-
tional freedom and results in a shorter
or kinked ASCH overall. The existence
of almost identical conformations of the
ASCH for AAK1 and BIKE in different
crystal forms suggests that this likely
reflects a stable, biologically relevant
conformation for substrate recognition.
Other key interactions of the activation
loop are conserved between all NAK fam-
ily members; for instance, the glutamate
side chain from the kinase Ala-Pro-Glu
(‘‘APE’’) motif (E229 in AAK1, Figure 1C)
forms a salt bridge that secures the
C terminus of the loop. Furthermore, the
conserved arginine and tyrosine residues
preceding the APE motif (residues Y225
and R226 in AAK1) appear to help lock
the activation segment into position.
Both GAK and MPSK1 structures sug-
gested that activation loop phosphoryla-
tion is not essential for assembly of the
regulatory spine (‘‘R spine’’; residues
constituting the R spine are highlighted
by red hexagons in Figure 1C), leading
to constitutively active proteins (Chaikuadet al., 2014; Eswaran et al., 2008; Kornev and Taylor, 2010). Simi-
larly, in structures of BIKE and AAK1 there is alignment of the
R spine in the absence of phosphorylation, suggesting that
NAK family members are constitutively active kinases (Fig-
ure 2C). In AAK1, M94 from the a-C helix, Y106 from b4, and
H174 and F195 from the HRD and DFG motifs, respectively,
constitute the assembled R spine. The corresponding residues in
BIKE (M99, Y111, H178, and F199) are also aligned. A 17-mer
synthetic peptide corresponding to the AAK1/BIKE phosphory-
lation site on the medium subunit of AP2 was used to test kinase
activity. Phosphorylation of the substrate in the presence of
AAK1 was confirmed by mass spectrometry (Figure S1). Similar
data were obtained for BIKE (data not shown). In kinases that rely
on activation segment phosphorylation for activity, typically the
phosphorylated residue interacts with the arginine of the HRD
motif to secure the activation loop and form an ordered substrate
binding groove. In the structures of BIKE, AAK1, and active GAK,
a salt bridge is formed between a glutamate residue in the ASCH
and HRD motif arginine that mimics this interaction (residues
R175 and E216 in AAK1). The rigid and anchored structure of
the activation segment highlights a NAK-specific structural
feature stabilizing the active state of these kinases.
Mechanisms of NAK Regulation Remain Poorly
Understood
The catalytic activity of AAK1 has been shown to be stimulated
by the binding and assembly of clathrin around the AP-2/AAK1
complex, resulting in increased phosphorylation of the m2 sub-
unit. Furthermore, clathrin was found to interact directly with
the kinase domain of AAK1 (Conner et al., 2003). Themechanism
for the increase in AAK1 activity in the presence of clathrin is
unclear, but the crystal structure presented here indicates that
the active conformation of AAK1 is not dependent on phosphor-
ylation, since dephosphorylated AAK1 is able to form a confor-
mation that is catalytically competent (Figure S1). It has been
speculated that the substrate binding site may be blocked in
the full-length protein by part of the C-terminal region of AAK1
in a pseudo-substrate type of interaction that can be removed
through clathrin binding (Jackson et al., 2003). At the C terminus
of AAK1, residues 846–852 correlate with the known NAK family
substrate consensus sequence, and was proposed as a poten-
tial pseudo-substrate (Jackson et al., 2003). However, evidence
later showed that clathrin stimulation also occurred in C-termi-
nally truncated constructs (Conner et al., 2003). The mystery of
AAK1 activation currently remains unsolved, and similarly little
is understood about the mechanisms of regulation of other
NAKs. In several of the GAK structures previously reported
(PDB: 4o38, 4c58, 4c59), each kinase domain forms a homo-
dimer that participates in activation segment exchange with its
interaction partner. We recently suggested that this represents
an inactive conformation of the catalytic domain due to the par-
tial unfolding of the activation segment, leading to the absence of
a substrate binding groove (Chaikuad et al., 2014). This dimer
could represent a mechanism of GAK inactivation at high con-
centration, such as may occur at the trans-Golgi and focal adhe-
sion sites, and thereby this could be specifically linked to GAK’s
function. Such a conformation has yet to be observed with other
members of the NAK family. Previous studies of MPSK1 have
indicated that it is monomeric (Eswaran et al., 2008), and our
data so far show that AAK1 and BIKE exist predominantly as
monomers (observed by gel filtration and crystallography). For
some kinases phosphorylation is thought to be necessary for
dimerization, for example the checkpoint kinase CHEK2 (Cai
et al., 2009). Phosphorylation mapping of AAK1 grown from
Escherichia coli showed that it is able to autophosphorylate at
several sites on the activation loop (T207, S235) and various
other sites across the protein (S115/S116, T144/T147, T170).
We used analytical ultracentrifugation (AUC) to show that these
phosphorylations appear to have little impact on the oligomeriza-tion state of the protein, since the major detectable species
matched themonomericmolecular weight (Figure 2D). Theminor
peak visible at 103 kDa likely corresponds to minor impurities
present in the sample, which were visible by SDS-PAGE (data
not shown), rather than the AAK1 dimer (expected mass of
87.4 kDa).
NAK Substrate Binding Site Structure Varies in
Accordance with Diverse Functional Roles
AAK1 and GAK are both known to bind to the medium subunit of
AP-2, and AAK1 and BIKE are both known interaction partners of
Numb. The four human NAKs are expressed across all tissue
types and, given that several of their substrates overlap, it is
unclear whether there is some functional redundancy between
the three kinases or whether each is required for recruitment of
different types of cargo (Conner and Schmid, 2003; Krieger
et al., 2013; Uhlen et al., 2015; Zhang et al., 2009). If the latter
is true, it can be reasoned that any differences in substrate selec-
tion and activity are most likely caused by factors other than the
sequence of the substrate binding site, since AAK1 and BIKE are
identical in sequence and structure across the substrate binding
groove (Figure 2E). In contrast, MPSK1 has an extended loop
between helices aF and aG that forms an additional helix (aFG
helix) at the substrate binding site and leads to a deeper cleft.
Both MPSK1 and GAK do not share a high degree of sequence
similarity in the substrate binding groove with AAK1/BIKE,
suggesting that these NAK family members recognize different
substrates and interaction partners in agreement with their
diverse biological functions.
Small Differences in NAK ATP Binding Sites Allow for
Specific Inhibitors
NAK family members do not conform to the typical consensus
sequence of the kinase glycine-rich loop (‘‘P loop,’’ a flexible
phosphate-binding loop at the ATP site; A53–A59 in AAK1):
the first and third glycine in the sequence G-X1-G-X2-4-G
are replaced by residues with lower conformational freedom
(Figure 1C). Despite this, the presence of a double-glycine
motif due to addition of a glycine in position X2 means that
the loop retains a high degree of flexibility. This is demon-
strated by the structures of BIKE where residues of this loop
have above-average B factors and the protein is able to
accommodate different inhibitor scaffolds through a change
in loop conformation.
At the ATP binding pocket, AAK1 and BIKE differ in only three
residues; two minor changes at the hinge region (D127 in AAK1
versus E131 in BIKE, and F127 versus Y132) and one change at
the P loop (A58 versus S63) (Figure 1C). GAK has one residue
fewer at the hinge region than other NAKs as well as the bulky ar-
omatic side chain of F133 that sits directly below the hinge and
forces the backbone of the hinge residue G128 upward, leading
to the ATP pocket of GAK being fractionally more enclosed at the
front (Figure S1). However, GAK compensates for this effect at
the back of the ATP pocket where T123 replaces methionine or
leucine in other NAK members, effectively making the pocket
deeper as well as adding a polar side chain (Figure S1). AAK1,
BIKE, and MPSK1 all have bulky aromatic residues on the
outside of the hinge region, replaced by L125 in the equivalent
position in GAK.Structure 24, 401–411, March 1, 2016 ª2016 The Authors 405
Figure 3. Clinical Kinase Inhibitor Binding to
NAKs
(A) Thermal shift assay data for a selection of clin-
ical inhibitors against each of the NAK family kinase
domains. See also Table S1 and Figure S2.
(B) ITC determination of thermodynamic parame-
ters for inhibitor compounds determined at 15C.
(C) ITC data measured for the interaction of ninte-
danib with AAK1 and BIKE. The data showed a
10-fold difference in affinity.
(D) The structure of nintedanib.
(E) The structure of SP600125.NAKs Bind a Wide Variety of Clinical Kinase Inhibitors
To probe the ATP binding pocket of NAK family members, we
screened all four kinases against a library of 144 clinically used
kinase inhibitors using a thermal shift assay (Fedorov et al.,
2012) (Table S1 and Figure 3A). The screening data showed a
surprisingly large number of compounds with a high DTm
(change in protein melting temperature) for one or all NAKs, sug-
gesting excellent druggability. Among the most significant hits
were the CHK1 inhibitor PF-477736, the JAK inhibitor momeloti-
nib, and the FLT3 inhibitor lestaurtinib. It is striking that many
kinase inhibitors that have been reported to have excellent selec-
tivity profiles in the literature interacted significantly with the NAK
family. However, NAKs are often omitted from selectivity panels,
including commercial screens. For instance, the JNK inhibitor
SP600125 interacted strongly with BIKE and AAK1 in our assay,
but showed good selectivity against 300 kinases (Anastassiadis
et al., 2011); however, the panel included only MPSK1 from the
NAK family (a non-binder in our assay and the most diverse
member of the family). Similarly, momelotinib selectivity was
profiled against approximately 150 different kinases, and of
these only eight had IC50 < 0.1 mM; however, no NAK family
members were screened (Pardanani et al., 2009). A recent study
byGao et al. (2013) profiled the binding of 158 small molecules to
234 kinases, providing an excellent overview of kinase inhibitor
specificity and kinase sensitivity, but no NAKs were included in
their panel. An inhibitor of the Aurora kinases and JAK2/3,
AT9283, was tested against >200 kinases, but it is not clear
whether NAKs were included (Dawson et al., 2010). We found
that AT9283 interacted strongly with NAKs, and affinity for
BIKE was confirmed by isothermal titration calorimetry (ITC)
(KD = 6 nM) (Figures 3A and 3B).
As expected from the similarity of their ATPbinding sites, AAK1
and BIKE strongly interacted with the same inhibitors (Figure 3A).
Correlation plots indicated very similar Tm shifts for BIKE versus
AAK1, suggesting that design of selective inhibitors will be
challenging (Figure S2). In contrast, GAK and MPSK1 showed406 Structure 24, 401–411, March 1, 2016 ª2016 The Authorssignificantly diverse interaction with this
inhibitor set, and some inhibitors showed
inhibition of only one NAK kinase. For
instance, ponatinib was specific for GAK,
the spleen tyrosine kinase inhibitor tamati-
nib interacted only with MPSK1, and the
protein kinase C inhibitor UCN-01 showed
preferential interaction with AAK1/BIKE.
We were interested in whether the
observed large values of DTm correlatedwith high binding affinity and determined dissociation constants
(KD) for a selection using ITC. AZD7762 (DTm 11
C and 13C,
respectively) had KD = 36.5 and 33.1 nM for AAK1 and BIKE,
respectively (Figure 3B). The large negative binding enthalpy
change indicated favorable polar interactions. The JAK inhibitor
baricitinib showed strong interaction for AAK1/BIKE in Tm assays
butmodest interactionwithMPSK1andGAK. ITCdata confirmed
strong interaction with AAK1/BIKE but revealed considerable
interaction with MPSK1 and GAK despite modest Tm shifts
(Figure 3B).
Crystallographic Insights into Inhibitor Selectivity
An interesting hit was nintedanib, a tyrosine kinase inhibitor in
development for the treatment of idiopathic pulmonary fibrosis,
which has a 10-fold higher affinity for BIKE than AAK1 (Figures
3C and 3D). The crystal structure of nintedanib in complex with
vascular endothelial growth factor receptor 2 (PDB: 3c7q) re-
vealed that the compound wraps around the outside of the hinge
region. Assuming that nintedanib exploits the same type of bind-
ing mode with NAKs, it could interact with the non-conserved
residues on the outside of the hinge (Figure 2E), which would
explain the observed difference in binding affinities.
Differences within the ATP binding pocket may account for
preferential binding of SP600125 to AAK1 and BIKE. SP600125
is a small, planar molecule (Figure 3E), and hydrophobic van
derWaals interactions appear to be crucial to its binding. In crys-
tal structures so far solved with SP600125 in complex with
various kinases (PDB: 1pmv [JNK3], 1uki [JNK1], and 2zmd
[TTK]), the presence of a methionine residue in the back of the
ATP pocket offers a critical hydrophobic Met-p interaction with
the aromatic ring. In AAK1 and BIKE, M126 and M130, respec-
tively, are capable of fulfilling this role, but for MPSK1 and GAK
the lack of methionine at this position most likely results in a
weakened interaction.
To obtain insights into the molecular details of ligand interac-
tion, we co-crystallized AAK1 with the broad-spectrum kinase
Figure 4. Small-Molecule Inhibitor Interactions with AAK1 and BIKE
(A) Interaction of K252a with AAK1. Inhibitors are shown in stick representation with yellow carbon atoms. Hydrogen bonds are indicated by dotted lines. Key
interacting residues are shown and labeled.
(B) Chemical structures of K252a and related compound lestaurtinib.
(C and D) Interaction of BIKE with (C) AZD7762 with (D) baricitinib. Inhibitors are shown in stick representation with yellow carbon atoms. Hydrogen bonds are
indicated by dotted lines. Key interacting residues are shown and labeled.
(E) Chemical structure of (5Z)-7-oxozeaenol.
(F) Denaturing mass spectra for NAKs in the presence of (5Z)-7-oxozeaenol.inhibitor K252a, and BIKE with the inhibitors baricitinib and
AZD7762 (Figures 4 and S3). As expected, the indolocarbazole
moiety of K252a interacted with the kinase hinge, whereas the
non-planar furanose tail extended out of the pocket in a similar
manner to that predicted by docking of K252a into a homology
model (Kuai et al., 2011). Lestautinib, closely related to K252a
(Figure 4B), was found to bind with high affinity to both
AAK1 and BIKE (DTm of 14
C and 17C, respectively). Based
on the structure of K252a with AAK1, lestaurtinib was manually
modeled in the binding pocket as shown in Figure S3.
BIKE was solved in complex with two clinically used kinase in-
hibitors, baricitinib and AZD7762 (Figures 4C and 4D). Baricitinib
has been reported to be a potent and selective inhibitor of JAK1/2,
and is currently being tested in phase III clinical trials for the treat-
ment of rheumatoid arthritis (Norman, 2014; Shi et al., 2014; van
Vollenhoven, 2013). The small molecule AZD7762, an inhibitor
of the checkpoint kinases CHEK1 and CHEK2, potentiates anti-tumor activity in pre-clinical studies of various cancers when
co-administered with other DNA-damage agents (Ashwell et al.,
2008; Grabauskiene et al., 2014; Landau et al., 2012; Morgan
et al., 2010; Zabludoff et al., 2008). Both inhibitors are ATP-
competitive, forming two H-bonding interactions with the back-
bone of the hinge at residues E131 and C133. Baricitinib is further
anchored in place by a polar interactions with Q137 and N185 at
the bottom of the ATP site. The ethyl-sulfonyl group of baricitinib
extends upward to interact with the P loop while, conversely,
AZD7762 makes very few interactions with residues 58–62.
Another notable difference between the BIKE structures is the
presence of a second ligand molecule of AZD7762 positioned
near the C terminus, forming p-p stacking interactions with a
symmetry-related molecule (Figure S1).
ITC measurements showed about a 10-fold increased affinity
of baricitinib for AAK1 and BIKE when compared with GAK
(Figure 3B). The crystal structures of GAK show that F133 ofStructure 24, 401–411, March 1, 2016 ª2016 The Authors 407
aBpushes the hinge upward, and the side chain of Q129 extends
further into the ATP site relative to the corresponding residues on
AAK1/BIKE, leading to non-optimal H-bonding distances with
the ligand and a potential clash that could account for this differ-
ence in selectivity.
JAK inhibitors with generally good selectivity (momelotinib,
AT9283, baricitinib, fedratinib, ruxolitinib, and gandotinib) inter-
acted strongly with NAKs in our assay and, given the low similar-
ity between these two kinase families and the diversity of ligand
scaffolds involved, such extensive overlap in inhibitor activity
was surprising. Unfortunately, the binding modes of JAK inhibi-
tors with strong NAK activity have not been determined crys-
tallographically. We can therefore only speculate that shared
dynamic properties such as inherent flexibility and domain plas-
ticity allow these kinases to accommodate similar ligand scaf-
folds. Ligand-interaction pattern searching (Kooistra et al.,
2016) can be used to identify JAK structures with protein-ligand
interactions similar to those of NAK-inhibitor complexes and
estimate the binding mode. For example, in the JAK2 structure
reported in PDB: 3fup, the ligand CP-690,550 shares a pyrro-
lopyrimidine hinge-binding motif with baricitinib, as well as a pri-
mary amine tail that extends up to make contact with the P loop
of JAK2 in a similar manner to the ethyl-sulfonyl group of barici-
tinib in the BIKE structure we reported here. We think therefore
that it is likely that the baricitinib binding mode is conserved
between NAKs/JAKs.
Active-Site Cysteine Residues Allow Irreversible
Inhibition by Covalent Modifiers
Other unanticipated hits in our ligand screening assay include
covalent inhibitors such as (5Z)-7-oxozeaenol (Figure 4E), an in-
hibitor of transforming growth factor b-activated kinase 1 (TAK1)
and mitogen-activated protein kinases (MAPKs) (Ohori et al.,
2007; Wu et al., 2013). Irreversible inhibition of these kinases
was found to be due to covalent binding of the ligand cis-enone
moiety to a cysteine residue at the base of the ATP pocket. The
crystal structures of AAK1, BIKE, and GAK reveal that these
kinases possess a cysteine residue (C193, C197, and C190,
respectively) at an equivalent position. In contrast, MPSK1 lacks
this cysteine residue and instead amethionine (M165) is situated
at this site (see Figure 1C). A high level of thermal stabilization in
the presence of (5Z)-7-oxozeaenol is observed for AAK1, BIKE,
and GAK, but not for MPSK1 (Figure 3A). Furthermore, when
(5Z)-7-oxozeaenol was incubated with each of the NAKs, a shift
in the observed molecular weight of each protein corresponding
to the addition of the molecular weight of compound (a shift of
around +132 Da in each case) can be observed using denaturing
mass spectrometry, indicating that the compound is covalently
bound except in the case of MPSK1 (Figure 4F). The kinase
domain of each NAK family member possesses between 7 and
13 cysteine residues in total, several of which are located on
the solvent-accessible surface of the protein. The mass spec-
trometry data confirm that only one inhibitor molecule is bound
to each catalytic domain despite incubation with a 3-fold molar
excess of covalent inhibitor and the high number of accessible
cysteine residues, suggesting that the interaction is specific for
the cysteine at the ATP pocket at the concentration used.
Indeed, other known irreversible inhibitors such as afatinib and
ibrutinib do not bind to the NAKs (Table S1). These inhibitors408 Structure 24, 401–411, March 1, 2016 ª2016 The Authorshave been found to bind preferentially to cysteine residues
located at the C-terminal region of the kinase hinge that is not
conserved in NAKs. This further suggests that the covalent
bond formation is specific for ligands that fit into the ATP site
with a reactive group at a position complementary to the reactive
side chain, and does not lead to global labeling of surface
cysteine residues. We modeled (5Z)-7-oxozeaenol into the bind-
ing site of BIKE using the crystal structure of ERK2 bound to
(5Z)-7-oxozeaenol (PDB: 3w55), which showed that the ligand
can be neatly accommodated at this site (Figure S3).
Inhibitor Optimization and Future Perspectives
The data presented here offer a starting point for further study of
these highly diverse kinases, offering potential for optimization of
specific inhibitors. In BIKE, for example, it should be possible to
expand into the pocket next to M130, which is occupied by a
molecule of ethylene glycol and several waters in the structure
with AZD7762, or by a string of water molecules in the structure
with baricitinib. Despite the extraordinary similarity of the ATP
binding sites of AAK1 and BIKE, by exploiting the different resi-
dues on the outside of the kinase hinge it may be possible to
selectively inhibit one of these proteins. It is highly probable
that this is the mechanism of the observed selective inhibition
of BIKE over AAK1 by nintedanib, although further crystal struc-
tures would be required to confirm our proposed binding mode.
Nevertheless, if the binding mode is indeed conserved, interac-
tion with diverse solvent-exposed regions would offer a strategy
for introducing selectivity between these closely related catalytic
domains. Combining the ATP-site selectivity possibilities with
similar cysteine-targeting functionality of (5Z)-7-oxozeaenol
may allow development of selective covalent NAK inhibitors.
As yet, a major question remains over the redundancy of func-
tion of AAK1, BIKE, and GAK, so it is not currently clear whether
there will be a need for multi-NAK-targeting ligands or whether
selectivity will be key. Since NAKs appear to play a role in
wide-ranging disease systems, it is indeed likely that the
required specificity will be disease dependent. Development of
various NAK-specific tool compounds would be a valuable addi-
tion to the future research of this family of proteins by helping to
distinguish between the various functional roles of each family
member and to pinpoint their specific disease contribution.
Our data show that NAKs bindwith high affinitymany inhibitors
that were previously thought to be selective for distantly related
kinases. One such example was already shown to have clinical
relevance: gefitinib was originally thought to be a selective inhib-
itor of epidermal growth factor receptor tyrosine kinase, but was
later also found to be a potent inhibitor of GAK in vivo and to
cause many of the clinical effects of the drug (Sakurai et al.,
2014; Tabara et al., 2011). It remains to be seen whether any of
the observed effects of other clinically tested inhibitors result
from off-target inhibition of members of this highly druggable
branch of the kinome.
EXPERIMENTAL PROCEDURES
Expression and Purification
MPSK113–305 was cloned, expressed, and purified as described by
Eswaran et al. (2008). AAK127–365 (crystallization) or AAK131–396 (AUC),
BIKE38–345(K320A,K321A), and GAK20–347 with tobacco etch virus (TEV)
protease-cleavable hexahistidine tags were expressed from the vectors
pNIC-CTH0, pNIC-ZB, and pNIC28-Bsa4, respectively. Transformed
BL21(DE3)-R3-pRARE cells (Novagen) were grown at 37C in Luria-Bertani
medium until OD600 reached 0.4–0.5, then cooled to 18
C and supplemented
with 0.5mM isopropyl 1-thio-D-galactopyranoside at an OD600 of 0.6 to induce
protein expression overnight. Cells were harvested by centrifugation, resus-
pended in lysis buffer (50 mMHEPES [pH 7.5], 500 mMNaCl, 5 mM imidazole,
5% glycerol, 0.5 mM tris(2-carboxyethyl)phosphine [TCEP], 1:2,000 protease
inhibitor cocktail for AAK1/BIKE; or 50 mM HEPES [pH 7.4], 500 mM NaCl,
20 mM imidazole, 5% glycerol, 0.5 mM TCEP, 0.2 mM PMSF for GAK) and
lysed by sonication on ice. Proteins were purified using Ni-Sepharose resin
(GE Healthcare) and eluted stepwise in binding buffer with 100–250 mM imid-
azole. Removal of the hexahistidine tag was performed at 4C overnight using
recombinant TEV protease either before (AAK127–365, BIKE) or after (GAK) gel
filtration (Superdex 200 16/60, GE Healthcare). GAK and BIKE were passed
over Ni-Sepharose resin as a final purification step. AAK127–365 was further
purified using cation exchange chromatography (5-ml HiTrap Q column, GE
Healthcare) to isolate the phosphorylation states. Proteins were characterized
by mass spectrometry and SDS-PAGE.
Crystallization and Data Collection
Purified AAK1 or BIKE was buffer-exchanged into 50 mM HEPES (pH 7.5),
300 mM NaCl, and 5% glycerol, and concentrated to 11 or 13 mg/ml,
respectively, using 30 kDa MWCO centrifugal concentrators (Millipore).
Concentrated proteins were centrifuged at 14,000 rpm for 10 min at 4C. In-
hibitor compounds in DMSO were added to a final concentration of 1.5 mM
(3% DMSO) and incubated on ice for approximately 30 min prior to setting
up 150-nl volume sitting drops at three ratios (2:1, 1:1, or 1:2 protein-inhibitor
complex to reservoir solution). Drops were equilibrated at two temperatures
(4C or 20C). Crystals were obtained under various conditions, and were
cryoprotected in mother liquor supplemented with 25% ethylene glycol
before flash-freezing in liquid nitrogen for data collection. The best-diffracting
crystals grew under the conditions described in Table 1. Diffraction data
were collected at the Diamond Light Source beamline I04 (AAK1) or I04.1
(BIKE).
Structure Solution and Refinement
Diffraction data for both the AAK1 and BIKE crystals were integrated using
MOSFLM (Leslie and Powell, 2007) and scaled using AIMLESS from the
CCP4 software suite (Winn et al., 2011). For AAK1, molecular replacement
was performed with Phaser (McCoy et al., 2007) using MPSK1 (PDB: 2buj)
as the searchmodel. For the two structures of BIKE, the refined AAK1 structure
was used as the search model. Density modification was performed with
Parrot (Zhang et al., 1997) prior to rebuilding using Buccaneer (Cowtan,
2006). Coot (Emsley et al., 2010) was used for manual model building and
refinement. REFMAC5 (Murshudov et al., 1997) and PHENIX (Adams et al.,
2010) were used for automated refinement, and MolProbity (Chen et al.,
2010) was used to validate the structures. Structure factors and coordinates
have been deposited in the PDB (see Table 1).
Sedimentation Velocity
Phosphorylated, hexahistidine-tagged AAK1(31–396) (molecular weight
43.7 kDa) was dialyzed into 25 mM HEPES (pH 7.5) and 150 mM NaCl, and
diluted to 1.5 mg/ml (A280 = 1 a.u.) prior to running experiments. Data were
measured at 40,000 rpm using absorbance optics in a Beckman XL-I Analytical
Ultracentrifuge equipped with a Ti-50 rotor. Two sector cells were filled with
sample and reference buffer. Data were analyzed using SEDFIT (Brown and
Schuck, 2006) to calculate c(s) distributions.
Thermal Shift Assay
Thermal shift assay was performed according to the general procedure
described by Fedorov et al. (2012). The purified catalytic domain-containing
constructs of AAK1, BIKE, GAK, and MPSK1 were tested against a library of
144 kinase inhibitor compounds that have been used in the clinic (Table S1).
In brief, in 96-well plate format, 19.5 ml of protein at 2 mMconcentration in assay
buffer (10 mM HEPES [pH 7.5], 500 mM NaCl) was incubated with SYPRO
Orange dye (1:1,000 dilution) and either 0.5 ml of compound (diluted from a
stock in 100% DMSO to give a final concentration of 12.5 mM compound
and 2.5% DMSO) or the equivalent volume of DMSO as a reference. SYPROOrange fluorescence intensity was measured at 25C–95C at a rate of 3C/
min using a real-time PCR instrument (Stratagene MxPro 3005), and DTm
calculated relative to an average of at least four reference wells. All measure-
ments were performed in triplicate andmean values were reported for all com-
pounds (Table S1).
Isothermal Titration Calorimetry
A VP-ITC or ITC200 (Malvern Instruments) was used to determine ligand bind-
ing affinity of various kinase inhibitors using the reverse-titration method. The
concentrated kinase was dialyzed overnight in assay buffer (25 mM HEPES
[pH 7.4], 150 mM NaCl, 0.5 mM TCEP) at 4C and loaded into the ITC syringe.
A stock solution of the compound at 10 or 50 mM in DMSO was diluted in dial-
ysis buffer and added to the ITC instrument cell. Serial injections of the protein
solution into the cell were made until saturation was observed. Experiments
were performed at 15C with 10–20 times the molar concentration of protein
titrated into ligand. Origin software was used to analyze the data, and binding
affinity was determined by fitting to a ‘‘one set of sites’’ model.
Protein Mass Spectrometry
A synthetic peptide substrate, residues 149–165 of the medium subunit of
AP2, ‘‘AP2M1tide’’ (SQITSQVTGQIGWRREG), was used to test activity of
dephosphorylated AAK1/BIKE. In 50 ml of total reaction volume, substrate
was diluted to 100 mM in 50 mM HEPES (pH 7.5), 5 mM MgCl2, 1 mM ATP,
0.5 mM TCEP, and 100 mM sodium orthovanadate. After 15 min incubation
at 37C, 250 nM purified kinase (or equivalent volume of buffer for control)
was added to initiate the reaction. Reaction was performed at 37C for 1 hr
with shaking (400 rpm). 1-ml aliquots of reaction mixture were quenched after
0 and 60 min by addition of 59 ml of 0.1% formic acid and loaded onto an elec-
trospray ionization time-of-flight (LC/MSD TOF) spectrometer (Agilent).
To test covalent inhibitor binding, we diluted purified protein to 1 mg/ml in
assay buffer (25 mM HEPES [pH 7.4], 150 mM NaCl, 0.5 mM TCEP). (5Z)-7-
oxozeaenol ((3S,5Z,8S,9S,11E)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-
methoxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione) (Merck) was
diluted 1:10 from a 10 mM DMSO stock into assay buffer, then incubated
with the protein at a final ligand concentration of 100 mM for 30 min at 4C.
2 ml of protein was denatured by the addition of 48 ml of 1% formic acid prior
to loading onto a mass spectrometer as before. The spectrum was deconvo-
luted using the instrument software.
Phosphorylation mapping was performed as described previously (Eswaran
et al., 2008).
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